Seres Therapeutics/MCRB

$0.58

-5.94%
-
1D1W1MYTD1YMAX

About Seres Therapeutics

Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Ticker

MCRB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Eric Shaff

Employees

233

Headquarters

Cambridge, United States

MCRB Metrics

BasicAdvanced
$94.73M
Market cap
-
P/E ratio
-$0.90
EPS
2.29
Beta
-
Dividend rate
$94.73M
2.2887
$6.73
$0.60
3.93M
1.778
1.477
-18.38%
-32.15%
-43.48%
0.75
1,672.24%
61.92%
56.09%

What the Analysts think about MCRB

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 5 analysts.
1,144.83% upside
High $15.00
Low $1.10
$0.58
Current price
$7.22
Average price target

MCRB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-100%
Net income
$-41.2M
-13.81%
Profit margin
0%
-100%

MCRB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 35.63%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.57
$0.36
-$0.37
-$0.32
-
Expected
-$0.55
$0.53
-$0.50
-$0.50
-$0.34
Surprise
3.85%
-32.57%
-26.21%
-35.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Seres Therapeutics stock?

Seres Therapeutics (MCRB) has a market cap of $94.73M as of April 19, 2024.

What is the P/E ratio for Seres Therapeutics stock?

The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of April 19, 2024.

Does Seres Therapeutics stock pay dividends?

No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Seres Therapeutics dividend payment date?

Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.

What is the beta indicator for Seres Therapeutics?

Seres Therapeutics (MCRB) has a beta rating of 2.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Seres Therapeutics stock price target?

The target price for Seres Therapeutics (MCRB) stock is $7.22, which is 1144.83% above the current price of $0.58. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Seres Therapeutics stock

Buy or sell Seres Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing